-
A new and as yet unpublished study has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.
-
The ECG in the Figure was obtained from a 23-year-old male who presented with a several day history of atypical chest pain. His ECG was interpreted as consistent with an early repolarization variant. Should anything else be considered in the differential?
-
The diagnosis of hyperhidrosis, or excessive sweating, is achieved by clinical inquiry rather than laboratory testing, though quantitative metrics are available for clinical research.
-
Neck pain is common among the general population. Half of those patients who report this symptom have persistent complaints at 1 year. At particular risk for persistent neck pain are those ages 45-59 years, those with chronic low back pain, and patients who ride their bicycles regularly.
-
Survival benefits in the first year after acute MI, in patients 65 years or older, seem to differ according to specific ACE I prescribed.
-
-
A new, and as of yet unpublished study, has raised increased concern about the relationship between rofecoxib (Vioxx), Mercks blockbuster COX-2 inhibitor, and cardiovascular events.
-
Viagra: Maximum Capacity at High-Altitudes?; FDA Actions.
-
The High Cost of MRSA; Treatment of Latent TB: A High Priority; The APRICOT HCV/HIV Co-infection Study.
-
Nitazoxanide (Alinia) is a broad spectrum antiparasitic agent, previously approved for use as an oral suspension for the treatment of cryptosporidiosis and giardiasis in children. It has now received FDA approval as a 500 tablet for the treatment of giardiasis in adolescents and adults.
